Proto-oncogene activation caused by retroviral vector integration can cause malignancies in gene therapy trials. This has led investigators to search for less genotoxic vectors with minimal enhancer activity and a decreased risk of influencing neighboring chromosomal gene expression after integration. We previously showed that foamy virus (FV) vectors expressing the canine CD18 gene from an internal murine stem cell virus (MSCV) promoter could cure canine leukocyte adhesion deficiency (LAD). Here, we have repeated these studies using a FV vector expressing canine CD18 from a phosphoglycerate kinase (PGK) gene promoter. In vitro analysis showed that this vector did not contain an enhancer that activated neighboring genes, and it expressed CD18 efficiently in canine neutrophils and CD34+ cells. However, dogs that received hematopoietic stem cells transduced with the PGK-CD18 vector continued to suffer from LAD, and sometimes died prematurely of the disease. These studies show that the PGK promoter cannot effectively replace the MSCV promoter in CD18-expressing FV vectors, and they suggest that vectors containing a strong promoter-enhancer may be necessary for the treatment of human LAD.
INTRODUCTION
Hematopoietic stem cell (HSC) gene therapy has the potential to cure many genetic diseases and there have been notable successes in the field treating immunodeficiencies 1-3 and metabolic diseases. 4 However, insertional mutagenesis and neighboring gene activation by the viral vectors used can cause clonal expansion and malignancies. [5] [6] [7] Thus, there is a need for less genotoxic vectors that efficiently transduce HSCs and express transgenes at adequate levels.
Gammaretroviral vectors contain strong viral long terminal repeat (LTR) promoters and enhancers that can activate neighboring genes after integration. These vectors preferentially integrate in actively transcribed genes and near transcription start sites, 8 making it likely that the large populations of transduced cells transplanted during HSC gene therapy contain clones with vector proviruses near protooncogenes. Self-inactivating gammaretroviral vectors may have improved safety because of deletions in the viral LTRs, 9,10 but they require internal promoters with their own potential genotoxicity. Similarly, lentiviral (LV) vectors may also lack strong viral promoterenhancers, but they have a tendency to integrate in actively transcribed genes 11 and depend on internal promoters for transgene expression. These internal promoters should ideally lack enhancer sequences, but still must provide therapeutic levels of transgene expression. For example, the mouse phosphoglycerate kinase (PGK) promoter controls a house-keeping gene and has minimal enhancer activity. 12 Gammaretroviral self-inactivating vectors and LV vectors containing internal PGK promoters have less potential for activating neighboring genes than similar vectors containing murine leukemia virus LTR promoters, 10, 13 and LV vectors containing a PGK promoter did not promote leukemia in a tumor-prone mouse model. 14, 15 It remains to be seen if the PGK promoter can provide therapeutic levels of transgene expression during HSC gene therapy.
Our research group and others have developed foamy virus (FV) vectors as an alternative vector system for HSC gene therapy that may have reduced genotoxicity. FVs, or spumaviruses are non-pathogenic retroviruses found in several mammalian species. 16 High-titer vector stocks can be produced that are free of replication-competent retrovirus [17] [18] [19] and efficiently transduce HSCs from mice, dogs and humans. [20] [21] [22] [23] [24] [25] [26] FV vectors have a slight preference for integrating near transcription start sites (less than gammaretroviral vectors) but no overall preference for integrating within transcription units or actively transcribed genes. 27 In addition, FV vector proviruses have reduced potential to activate neighboring genes compared with gammaretroviral or LV vectors, because of a lack of enhancer activity and readthrough transcription in the viral LTRs. 13 These findings suggest that FV vectors are less likely to integrate near cellular proto-oncogenes, and also less likely to activate whatever genes are present near integration sites. This is supported by HSC transplantation experiments in dogs that showed no enrichment of FV vector proviruses near proto-oncogenes and no post-transplantation expansion of integrants near genes involved in cell proliferation, signal transduction or kinase activity. 28 Leukocyte adhesion deficiency (LAD) is an immunodeficiency caused by mutations in the leukocyte integrin ITGB2 gene also known as CD18. Failure to express the CD11-CD18 adhesion complex on the leukocyte cell surface prevents adhesion to the vascular endothelium and migration to sites of infection, resulting in life-threatening infectious complications. 29 Canine LAD (CLAD) is a large animal model of the human disease caused by a single nucleotide G-to-C transversion that replaces a cysteine with serine at residue 36 (C36S) in the N-terminal extracellular portion of the CD18 protein. 30 Dogs with CLAD suffer from many of the same symptoms as humans, and die prematurely of infections. 31 We previously used an FV vector that expresses the canine CD18 gene from an internal murine stem cell virus (MSCV) LTR promoter 32 to transduce CLAD HSCs and transplant partially myeloablated, autologous recipients. 28 This produced long-term leukocyte marking rates of 5-10% based on CD18 expression, and the animals remain healthy up to 4 years after gene therapy (unpublished results). Importantly, there was no evidence for clonal expansion of transduced cells based on an extensive integration site analysis. 28 Although this study suggests that a similar FV vectorexpressing human CD18 from an internal MSCV promoter would be curative for LAD, we had concerns that the strong viral enhancer in the internal MSCV promoter might still lead to neighboring protooncogene activation in some situations. Thus, we felt it would be preferable to use a vector containing an internal promoter with less enhancer activity. Here, we describe experiments in which dogs with CLAD were treated with an FV vector expressing canine CD18 from a PGK promoter.
RESULTS

Ex vivo promoter comparison
We previously used FV vector DFMscvCD18 (DF for 'Deleted Foamy' backbone) containing a viral MSCV promoter to successfully treat CLAD animals. 28 Here, we compared this vector with others that used either the PGK promoter from the mouse Pgk1 gene or the EF1a promoter from the human eukaryotic translation elongation factor 1 alpha 1 gene (EEF1A1). Like the PGK promoter, the EF1a promoter controls a ubiquitously expressed gene 33 that functions well in hematopoietic cells. [34] [35] [36] We used an intron-deleted version of the EF1a promoter that expresses at high levels 35 and has significantly reduced genotoxicity compared with gammaretroviral LTRs 10 to avoid possible splicing in FV vectors.
FV vectors expressing canine CD18 from either an internal MSCV or PGK promoter (DFMscvCD18 and DFPCD18, respectively) were compared initially. High-titer vector stocks were used to transduce CD34+ cells from CLAD animals at the same multiplicity of infection (based on vector genome-containing particles), and expression levels were analyzed by flow cytometry. In order to assess function in neutrophils (a clinically relevant cell type), the CD34+ cells were differentiated in vitro for 2 weeks down the neutrophil lineage, and then analyzed for expression of CD18. The MSCV promoter conferred high-level CD18 expression equivalent to that seen in normal (non-CLAD) cells, while the level of expression from the PGK promoter was much lower on a per cell basis (Figure 1a) . In order to improve expression of the PGK-based vector, we codon optimized the canine CD18 gene and produced vector DFPCD18opt. This vector showed significantly better expression than the non-optimized vector on a per cell basis, although the percentage of CD18+ cells remained lower than that obtained with the MSCV promoter ( Figure 1a) . We also tested an FV vector with the EF1a promoter driving codon-optimized canine CD18 gene (DFECD18opt). However, expression from this vector was very low in neutrophils and almost indistinguishable from that observed in untransduced CLAD cells (Figure 1a) .
We measured CD18 expression levels from the same vectors in CD34+ cells cultured for 5 days in vitro without differentiation down a specific lineage. A similar pattern of gene expression was observed, with CD18 levels decreasing in magnitude in the following order DFMscvCD184DFPCD18opt4DFPCD184DFECD18opt (Figure 1b) . These experiments suggested that the DFPCD18opt vector with a PGK promoter driving a codon-optimized CD18 gene would be the best choice for achieving potentially therapeutic expression levels from a cellular promoter. Importantly, some of the cells transduced by DFPCD18opt had CD18 expression levels within the range of normal cells. We also tested a slightly modified version of the DFPCD18opt vector called DFPCD18opt-oa containing a lac operator sequence tag in the LTR to facilitate the recovery of vector sequences from transduced cells (a feature not used in this study). This vector had similar expression to DFPCD18opt (Figure 1b ) and was chosen for transplantation experiments (see below).
Neighboring gene activation
We previously developed a transient transfection assay to measure neighboring gene activation by vector proviruses. 13 In this assay, plasmids containing vector proviruses are nucleofected into human K562 cells, and expression of a linked luciferase gene downstream of an enhancerless, minimal promoter and internal ribosome entry site is measured ( Figure 2 ). We compared FV CD18 vector proviruses and found that those with either the PGK or EF1a promoters produced significantly less luciferase expression than DFMscvCD18, as expected. In addition, the DFPCD18opt provirus resulted in slightly lower luciferase levels than the DFECD18opt provirus, suggesting that the EF1a promoter may be more likely to activate neighboring genes after integration. These results also supported our choice of the PGK promoter for CLAD transplantation experiments.
Transplantation and engraftment of transduced CLAD CD34+ cells
Bone marrow CD34+ cells were harvested from four CLAD dogs, and transduced with DFPCD18opt-oa vector stocks. Transduction was by a single overnight exposure to vector at a dose optimized for transduction of CD34+ cells. The dogs ranged in age from 6 to 8 weeks, and received 2.8-3.3Â10 6 CD34+ cells kg -1 (Table 1) after overnight transduction. They also received partial myeloablation with a dose of 200 cGy total body irradiation 1 day before transplantation. The pre-transplant transduction frequencies were determined by measuring CD18 expression in a portion of the cells cultured for 3 additional days after the infusion. These ranged from 6 to 13%, which was similar to the maximum transduction frequency we were able to obtain with this vector in CD34+ cells. Higher vector doses produced a minimal increase in CD18+ cells (data not shown) and presumably led to multiple integrations per cell. Transduction levels of 10-20% are typical for FV vectors in canine CD34+ cells, 23 and the requirement that CD11 also be expressed in cells may have limited our ability to detect CD18. 37 We assessed the marking rates by flow cytometry of peripheral blood leukocytes from each dog following transplantation ( Figure 3) . Two of the dogs (Venus and Vader) never achieved 41% CD18+ cells. Both remained ill and died o100 days after transplantation (see below). Two other dogs (Chico and Sonoma) also had o1% CD18+ leukocytes for the first 3-4 months, but they survived, and their marking rates climbed to 2.3 and 3.6% CD18+ leukocytes respectively 52 weeks after transplantation. Marking in specific cell subsets was also measured by flow cytometry, with the lowest and highest marking rates seen in neutrophils and T lymphocytes respectively ( Figure 3 ). These differences may be due to a combination of factors, including selective extravasation of CD18+ neutrophils from peripheral blood, and a growth advantage for CD18+ lymphocytes.
A similar phenomenon was observed previously in CLAD dogs treated with the DFMscvCD18 FV vector 28 or allogeneic bone marrow transplantation. 38 As seen in Figure 4 , the CD18+ lymphocytes from Chico and Sonoma proliferated well in response to the mitogen staphylococcal enterotoxin A, based on their loss of the fluorescent label carboxyfluorescein diacetate succinimidyl ester. In the two surviving dogs, marking rates continued to increase slowly in all cell types.
We also measured transduction frequencies by quantitative PCR of leukocyte DNA from many of the same blood samples (Figure 3) . Typically, the number of proviruses detected by PCR was slightly higher than the number of CD18+ cells detected by flow cytometry. This could be due to the presence of multiple provirus copies in some CD18-expressing cells, silencing of transduced cells containing a provirus, or a relative insensitivity of flow cytometry for cells expressing low levels of CD18. In order to address this issue, we flow-sorted CD18+ and CD18À leukocytes from Sonoma 52 weeks after transplantation and found that these cell subsets contained 0.97 and 0.027 provirus copies per cell as measured by quantitative PCR. Therefore, most CD18+ cells contained a single copy of the FV vector provirus. The presence of vector proviruses in the CD18À flow-sorted cell population can account for the higher marking rates measured by quantitative PCR and could be due either to inadequate expression for flow-sorting or silencing of the CD18 transgene.
Integration site analysis
Although the marking rates were low in these animals, it was still possible that a single clone predominated in the transduced cell population. We used linear amplification mediated (LAM)-PCR to determine the locations 24 and 28 vector proviruses in the peripheral blood cells of Chico and Sonoma at 18 and 20 months posttransplantation, respectively (Supplementary Table 1 ). Of these 52 integration sites, 18 (35%) were within RefSeq genes, 20 (38%) were within 15 kb of transcription start sites and 4 (7.7%) were within 30 kb of known cellular proto-oncogenes (MAML2, FGFR1, MEIS1 and RUNX1T1). These percentages were not statistically different (P40.05) than those observed in the 466 FV vector integration sites previously identified in CLAD dogs treated with an MSCV-CD18 FV Foamy virus PGK-CD18 vector for CLAD TR Bauer Jr et al vector. 28 In addition, each of the four integration sites present near proto-oncogenes was recovered in only a small percentage of all the sequencing reads with mappable junctions obtained for each animal (Supplementary Table 2 ), suggesting that they did not dominate the population of CD18+ cells. Taken together, these data demonstrate that CLAD dogs treated with the DFPCD18opt-oa vector maintain a polyclonal population of transduced blood cells.
Clinical course of transplanted dogs
All transplanted animals were carefully monitored for signs of infection, and treated according to our standard protocols for CLAD animal veterinary care. As shown in Figure 5a , the four animals that received the FV vector were frequently febrile, and required both antibiotics and admission to the intensive care unit. Venus and Vader were euthanized because of complications of CLAD disease at 75 and 91 days after transplantation, respectively, which is similar to the clinical course of CLAD dogs that do not undergo gene therapy but receive equivalent veterinary care in our animal facility. 28 Venus had mandibular swelling because of cranio-mandibular osteodystrophy, and persistent high fever. Vader had lameness because of hypertropic osteodystrophy, otitis externa, high fever and leukocytosis. Chico and Sonoma survived more than 1 year after transplantation, which is an unusually long life span for CLAD animals, suggesting that there may have been some therapeutic effect of the gene therapy. In addition, the elevated white blood cell count typical of CLAD largely resolved in these animals, consistent with improved leukocyte function (Figure 5b ). However, both animals continued to suffer from CLAD, experiencing recurrent infections and requiring aggressive antibiotic therapy to survive.
DISCUSSION
In this study, we used an FV vector expressing an optimized canine CD18 gene from a PGK promoter to treat CLAD animals by HSC gene therapy. The PGK promoter was chosen because of its lack of enhancer activity in assays of neighboring gene activation, and its relatively high expression level in neutrophils and CD34+ cells. Although there was polyclonal marking and a therapeutic response to the treatment, including a normalization of the white blood cell count and a restoration of lymphocyte proliferation after antigen stimulation, the treated animals continued to suffer from infections and two out of four died prematurely. These results are markedly different than those obtained when using an internal MSCV promoter to drive CD18 expression in an FV vector, which resulted in higher marking rates, a complete resolution of infectious symptoms, and a cure of the disease phenotype. 28 Presumably, the higher transduction frequency and expression level obtained from the MSCV promoter is required to provide a full therapeutic effect. Our study underscores the importance of using a relevant large animal disease model for testing vector designs, as in vitro testing suggested that the PGK promoter might be therapeutic. The marking rates of the PGK vector used in this study were lower than those obtained previously with an FV vector containing an MSCV promoter, despite an identical transduction and transplantation protocol. This was true both in cultured cells and in transplanted animals. The reason for the poor in vitro expression is not clear, but was not due to a low multiplicity of infection, because higher vector doses did not appreciably increase the percentage of CD18+ cells. It may be that a higher CD18 expression level is required to provide adequate pairing with CD11 and allow reliable detection of heterodimers on the cell surface by flow cytometry. Other factors could also limit expression from the PGK promoter, as similar transduction rates of 10-20% were observed with an FV vector-expressing green fluorescent protein from the same PGK promoter in canine CD34+ cells. 23 The low levels of CD18+ cells observed in vivo after transplantation may reflect the same phenomenon, although in this case inadequate CD18 expression could also impact a variety of physiological parameters such as engraftment, proliferation and extravasation. Importantly, a low in vitro marking rate obtained with the MSCV-CD18 FV vector (13.7%) still produced a cure of CLAD after transplantation, 28 so inadequate transduction in vitro cannot fully explain the poor clinical efficacy of the PGK promoter vector. In the case of human CD34+ cells, transduction levels of over 50% can routinely be obtained with FV vectors, even when assaying severe combined immunodeficient mouse-repopulating cells. 20, 21, 24 This may reflect species-specific tropism of wild-type FV, and suggests that the result obtained in a human clinical trial should be superior to those obtained in the dog model.
In conclusion, our findings raise important concerns about the use of alternative promoters in HSC gene therapy. Although the decrease in genotoxicity expected from promoters with minimal enhancer activity is a desirable goal, they must still provide a therapeutic transgene expression level. In the case of CLAD, the PGK promoter does not appear to produce a therapeutic expression level in vivo, even when the transgene is codon optimized. A related study also showed that LV vectors expressing CD18 from the EF1a promoter failed to cure CLAD dogs. 39 Thus, we are left with a difficult decision when translating the results obtained in the dog model to a human clinical trial: whether to use a strong viral promoter and enhancer such as MSCV that can provide a therapeutic expression level, or to continue testing alternative promoters until one can be found that provides adequate expression. This decision is further complicated by the fact that CLAD dogs treated with an FV vector containing an MSCV promoter remain cured 44 years after transplantation with no sign of leukemia or clonal expansion (our unpublished results), and because many patients with LAD currently die from their disease or complications resulting from allogeneic HSC transplantation. Therefore, an FV vector-expressing CD18 from an internal MSCV promoter may be a safe enough option to treat critically ill LAD patients, despite a theoretical risk of proto-oncogene activation due to insertional mutagenesis. It is possible that this theoretical risk could be further reduced by the inclusion of insulator elements or other modifications of the vector backbone, 40 but this remains to be demonstrated in the FV vector system.
MATERIALS AND METHODS
Animal procedures
All animal protocols were approved by the NCI Institutional Animal Care and Use Committee. CLAD animals were treated prophylactically with oral amoxicillin/potassium clavulanate on diagnosis of CLAD. More intensive treatment with parenteral antibiotics, fluids and analgesics were provided when necessary. Bone marrow CD34+ cells were isolated and stored as described previously. 28 Transplant recipients received 200 cGy of total body irradiation delivered from a 60 Co source 1 day before infusion of autologous transduced cells. Peripheral blood samples were obtained at multiple timepoints, and cell counts and differentials were performed by Antech Diagnostics (Lake Success, NY, USA) or the NIH Clinical Center laboratory.
Plasmids and vectors
All FV vectors were based on the pDF backbone 17 and prepared by four plasmid transfection as described. 17 Plasmids used in the neighboring gene activation assay (Figure 2 ) contained two-LTR proviral forms of each vector tested in the pACT5 backbone. 13 
Transduction conditions and measurements
CD34+ bone marrow cells were transduced by a single overnight infection as described, 28 after first determining the optimal vector dose on cultured CLAD CD34+ cells to ensure maximal transduction frequencies were obtained before transplantation. CD34+ cells were cultured for 3 additional days after infusion in Stemspan SFEM media (Stemcell Technologies, Vancouver, BC, Canada) containing 10% fetal bovine serum and 50 mg ml -1 human granulocyte colonystimulating factor (Neupogen; Amgen, Thousand Oaks, CA, USA), canine SCF (R&D Systems, Minneapolis, MN, USA) and human Flt3-L (Miltenyi Biotec, Auburn, CA, USA) before measuring ex vivo transduction frequencies. CD18 expression was measured by flow cytometry with a mouse antibody to canine CD18 (CA1.4E9; Serotec, Raleigh, NC, USA). Neutrophil and monocyte populations, as well as lymphocyte subsets, were analyzed as described using specific antibodies. 38 In vitro analysis of neutrophils derived from CD34+ cells was performed by culturing transduced CD34+ cells as above for 4 days, then adding 50 ng ml -1 canine IL-6 (R&D Systems), canine GM-CSF (R&D Systems) and human TPO (R&D Systems) for an additional 10 days to promote myeloid differentiation. After culture, neutrophil populations were assayed by immunostaining with an anti-canine neutrophil antibody (CADO48A; VMRD, Inc., Pullman, WA, USA). FV vector provirus copy numbers were determined by isolating genomic DNA from blood cells as described. 28 Lymphocyte proliferation assays were performed as described. 28 
LAM-PCR
Genomic DNA was purified from peripheral blood leukocytes by using a Wizard genomic DNA purification kit (Promega Corp., Madison, WI, USA). Vector junction sequences underwent two rounds of linear amplification using 100 ng of genomic DNA, 0.25 pmol of the FV vector-specific 5¢ biotinylated primer (5¢-GAACCTTGTGTCTCTCATCCC-3¢) and 2. DNA was ligated to enzyme-specific double-stranded linkers (5¢-GACCCGGG AGATCTGAATTCAGTGGCACAGCAGTTAGG-3¢/5¢-CATGCCTAACTGCTGT GCCACTGAATTCAGATC-3¢ for Fat I and 5¢-GACCCGGGAGATCTGAATT CAGTGGCACAGCAGTTAGG-3¢/5¢-AATTCCTAACTGCTGTGCCACTGAAT TCAGATC-3¢ for Tas I) using a Fast-Link DNA ligation kit (Epicentre Biotechnologies, Madison, WI, USA). Exponential amplification of ligated products was performed using 12.5 pmol each of FV vector-specific primer (5¢-GTCTATGAGGAGCAGGAGTA-3¢) and linker cassette-specific primer (5¢-GACCCGGGAGATCTGAATTC-3¢). In all, 8% of the first exponential PCR reaction was then used as template for a second, nested PCR amplification with 12.5 pmol each of nested FV vector-specific primer (5¢-CCTCCTTCCCTGTAA TACTC-3¢) and nested linker cassette-specific primer (5¢-AGTGGCACAG CAGTTAGG-3¢) using conditions identical to the first PCR. DNA sequencing was performed on products from the second, nested PCR amplification that had been cloned into a pCR4-TOPO vector by using a TOPO TA cloning kit (Invitrogen Corp., Carlsbad, CA, USA). FV vector integration sites were mapped to the dog genome as described. 28 Statistical comparisons with previous integration site data sets were performed by Fisher's exact test.
